| Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2 (NCT00844064) | Isarna Therapeutics GmbH | 2005-01-01 |
| Surgery for Pancreatic Tumors and Collection of Tumor Tissue for Study (NCT00100321) | National Cancer Institute (NCI) | 2004-12-21 |
| Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer (NCT00102752) | Threshold Pharmaceuticals | 2004-12-01 |
| Trial of Curcumin in Advanced Pancreatic Cancer (NCT00094445) | M.D. Anderson Cancer Center | 2004-11-01 |
| Biliary Tissue Sampling Using a Cytology Brush or the GIUM Catheter (NCT00160836) | University Hospital, Geneva | 2004-10-01 |
| Randomized Trial of EUS Neurolysis in Pancreas Cancer (NCT00279292) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2004-08-01 |
| Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer (NCT00242190) | University of Michigan Rogel Cancer Center | 2004-06-01 |
| Acupuncture For Pancreatic Cancer Pain (NCT00136669) | Memorial Sloan Kettering Cancer Center | 2003-09-01 |
| Malignant Obstruction ZILVER Against Routine Therapy (MOZART I) (NCT00196105) | Cook Group Incorporated | 2003-09-01 |
| Hyperthermia With Chemotherapy for Locally Advanced or Metastatic Pancreas Cancer (NCT00178763) | The University of Texas Health Science Center, Houston | 2003-09-01 |
| A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia (NCT00060502) | Centocor, Inc. | 2003-04-01 |
| Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer (NCT00191568) | Eli Lilly and Company | 2002-10-01 |
| A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer (NCT00034827) | Pfizer | 2002-01-01 |
| The Efficacy and Safety of Gemcitabine in Combination With Docetaxel to Treat Pancreatic or Biliary Cancer (NCT00268840) | ARCAGY/ GINECO GROUP | 2001-08-01 |
| Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver (NCT00041808) | FeRx | 2001-07-01 |
| Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma (NCT00201838) | Ohio State University Comprehensive Cancer Center | 2001-07-01 |
| Institut Paoli-Calmettes Pancreatic Neoplasms Database (NCT02869581) | Institut Paoli-Calmettes | 2000-01-01 |
| Single-centre Propensity Score-matched Comparison of Laparoscopic Versus Open Pancreatoduodenectomy (NCT05110573) | General Hospital Groeninge | 2000-01-01 |
| Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer (NCT00041639) | Gilead Sciences | 2000-01-01 |
| Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer (NCT00005648) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 1999-11-01 |
| Study of Gemcitabine Chemoradiation and TNP-470 Patients Locally Advanced, Nonmetastatic Adenocarcinoma of Pancreas (NCT00038701) | M.D. Anderson Cancer Center | 1999-08-01 |
| A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab (NCT00001805) | National Cancer Institute (NCI) | 1999-03-01 |
| Pancreatic and Periampullary Tumors in Greenland Inuit (NCT05595811) | Rigshospitalet, Denmark | 1999-01-01 |
| A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas (NCT00001431) | National Cancer Institute (NCI) | 1995-02-01 |
| Safety Study of Adjuvant Gemcitabine Started One Week After Laparoscopic Distal Pancreatectomy for Adenocarcinoma (NCT01045941) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Outcome of Pancreatic Stump Closure Following Resection of Tumors of the Head of the Pancreas. (NCT00419614) | Hillel Yaffe Medical Center | |
| Aroplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer Resistant to Standard Therapies (NCT00081549) | Aronex Pharmaceuticals | |
| A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas. (NCT00035035) | Eli Lilly and Company | |